6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors were tested for these tumors in clinical trials. In a screen for novel drugs that selectively...

Full description

Bibliographic Details
Main Authors:	Issaeva, N, Thomas, H, Djureinovic, T, Djurenovic, T, Jaspers, J, Stoimenov, I, Kyle, S, Pedley, N, Gottipati, P, Zur, R, Sleeth, K, Chatzakos, V, Mulligan, E, Lundin, C, Gubanova, E, Kersbergen, A, Harris, A, Sharma, R, Rottenberg, S, Curtin, N, Helleday, T
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
by: Gottipati, P, et al.
Published: (2010)

miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.
by: Moskwa, P, et al.
Published: (2011)

Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
by: Ying, S, et al.
Published: (2012)

6-Thioguanine and Its Analogs Promote Apoptosis of Castration-Resistant Prostate Cancer Cells in a BRCA2-Dependent Manner
by: Luna Laera, et al.
Published: (2019-07-01)

PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells
by: Cathy Su, et al.
Published: (2017-10-01)

Exploring the Synergy between PARP and CHK1 Inhibition in Matched <i>BRCA2</i> Mutant and Corrected Cells
by: Hannah L Smith, et al.
Published: (2020-04-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine.
by: Shepherd, P, et al.
Published: (1991)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
by: Juan Miguel Baquero, et al.
Published: (2022-05-01)

Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia.
by: Key, N, et al.
Published: (1987)

PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview
by: Islam Kourampi, et al.
Published: (2023-01-01)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
by: Maria Ornella Nicoletto, et al.
Published: (2023-06-01)

Cover 1 - Thioguanine Abrogated Colitis Cancer Model
Published: (2021-01-01)

Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors
by: Ciara C. O'Sullivan, et al.
Published: (2014-02-01)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
by: Man Yee Keung, et al.
Published: (2020-03-01)

Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
by: K. V. Menshikov, et al.
Published: (2022-06-01)

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
by: Paola Francica, et al.
Published: (2018-12-01)

Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
by: Kimiyo N Yamamoto, et al.
Published: (2014-01-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
by: Shicheng Yang, et al.
Published: (2023-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
by: Tingting Du, et al.
Published: (2022-07-01)

Thioguanine versus mercaptopurine in ALL97: thiopurine metabolism and treatment outcome
by: Lennard, L, et al.
Published: (2008)

6-Thioguanine Inhibits Herpes Simplex Virus 1 Infection of Eyes
by: Deyan Chen, et al.
Published: (2021-12-01)

The investigation of interaction between Thioguanine and human serum albumin by fluorescence and modeling
by: Xin An, et al.
Published: (2017-05-01)

The CST complex mediates end protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-deficient cells
by: Barazas, M, et al.
Published: (2018)

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
by: Khyati Meghani, et al.
Published: (2018-04-01)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
by: Yosuke Hirotsu, et al.
Published: (2020-05-01)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
by: Shan Li, et al.
Published: (2021-10-01)

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
by: Nicola Curtin, et al.
Published: (2020-11-01)

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
by: Reisländer, T, et al.
Published: (2019)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
by: Tacconi, E, et al.
Published: (2019)

Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition
by: Zhang Zheng, et al.
Published: (2024-03-01)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
by: Eliana MC Tacconi, et al.
Published: (2019-07-01)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
by: Diar Aziz, et al.
Published: (2021-08-01)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
by: Sayra Dilmac, et al.
Published: (2023-07-01)

PARP Inhibitors for Breast Cancer: Germline <em>BRCA1/2</em> and Beyond
by: Maria Clara Saad Menezes, et al.
Published: (2022-09-01)

In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers
by: Fengqin Yan, et al.
Published: (2023-02-01)

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
by: Geoffrey I Shapiro, et al.
Published: (2023-11-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
by: Yu-Yi Chu, et al.
Published: (2022-10-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)